Berberine Blood Pressure Randomized Trial: What the Evidence Says

Quick Answer

Berberine Blood Pressure Randomized Trial has 1 source documents in the current Migaku evidence database. The strongest available sources in this first pass are randomized trial, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 randomized trial.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• Objectives To evaluate the efficacy and safety of berberine in reducing VAT area and liver fat content in diabetes-free individuals with obesity and metabolic dysfunction-associated steatotic liver disease (MASLD). [Lei L (2026); evidence level 2]
• Berberine was associated with larger reductions in low-density lipoprotein cholesterol (-7.72 [95% CI, -13.13 to -1.93] mg/dL), apolipoprotein B (-3.42 [95% CI, -6.33 to -0.51] mg/dL) and high-sensitivity C-reactive protein (hs-CRP) (-0.072 [95% CI, -0.140 to -0.004] mg/dL) vs placebo, but not other secondary outcomes. [Lei L (2026); evidence level 2]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is trial evidence in the current set, but population and intervention details still matter. For berberine blood pressure randomized trial, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Lei L (2026). Berberine and Adiposity in Diabetes-Free Individuals With Obesity and MASLD: A Randomized Clinical Trial.. DOI: 10.1001/jamanetworkopen.2025.54152. PMCID: PMC12811813. PMID: 41543854. https://pmc.ncbi.nlm.nih.gov/articles/PMC12811813/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.